乌司他丁治疗急性胰腺炎的临床疗效评价

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (7): 828-830.

乌司他丁治疗急性胰腺炎的临床疗效评价

曾连山, 陈念平, 林木生, 莫艾, 周宇¹, 黄存林²

广东医学院附属医院普外科, ¹消化内科, 湛江524001, 广东;
²湛江南油医院外科, 湛江524057, 广东

收稿日期:2004-05-14 修回日期:2004-07-05 出版日期:2004-07-26 发布日期:2020-11-20
通讯作者: 曾连山,男,医学学士,副主任医师,主要从事胃肠和肝胆胰疾病的临床研究。Tel:13822521008 E-mail:zls2387@163.com

Clinical evaluation of efficacy of ulinastatin in treatment of patients with acute pancreatitis

ZENG Lian-Shan, CHEN Nian-Ping, LIN Mu-Sheng, MO Ai, ZHOU Yu, HUANG Cun-Lin

Department of Hepatobiliary Surgery,¹Department of Gastro Enterology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, Guangdong, China;
²Department of General Surgery, Nan-You Hospital, Zhanjiang 524057, Guangdong, China

Received:2004-05-14 Revised:2004-07-05 Online:2004-07-26 Published:2020-11-20

摘要/Abstract

摘要： 目的: 观察乌司他丁(UTI)治疗各型急性胰腺炎(AP)的临床疗效。方法: 将102 例急性胰腺炎患者随机分成2 组,对照组51 例(轻症38 例、重症I 型13 例);治疗组51 例(轻症38 例、重症I 型13 例)。对照组采用综合基础治疗,治疗组在综合基础治疗的基础上加用乌司他丁。按痊愈、显效、有效和无效四级评定疗效。结果: 治疗组轻症有效率为92.1 %,重症I 型为84.6 %;对照组轻症有效率为71.1 %,重症I 型为38.5 %,两组有显著差异性(P<0.05),治疗组对腹痛、血尿淀粉酶、白细胞和TB等的恢复明显优于对照组(P<0.05)。结论: 乌司他丁用于治疗急性水肿型胰腺炎和重症I型均有较好疗效,不良反应较少。

关键词: 乌司他丁, 急性胰腺炎, 治疗, 药效学, 随机对照研究

Abstract: AIM: To observe the clinical effects of ulinasta-tin (UTI) in treatment of patients with acute pancreatitis (AP).METHODS: 102 patients with acute pancreatitis were randomly divided into two groups.There were 51 cases (38 cases of light type, 13 cases of severe type I) in control group, which were given conventional treatment.There were 51 cases (38 cases of light type, 13 cases of severe type I) in treatment group, which were given conventional treatment and UTI.Clinical results were assessed as cured, significant effective, effective and non-effective.RESULTS: The effective rate was 92.1 %in light type, 84.6 % in severe type I in treatment group, while the effective rate was 71.1 % in light type, and 38.5 %in severe type I in control group (P<0.05).The therapeutic effects in treatment group were better than those of in control group (P<0.05) for releasing abdominal distention, amylase, white blood cells and TB.CONCLUSION: UTI is an effective agents in treating AP (light type and severe type I) with fewer side effects.

Key words: ulinastatin, acute pancreatitis, treatment, pharmacodynamics, randomized controlled trial

中图分类号:

R969.4

曾连山, 陈念平, 林木生, 莫艾, 周宇, 黄存林. 乌司他丁治疗急性胰腺炎的临床疗效评价[J]. 中国临床药理学与治疗学, 2004, 9(7): 828-830.

ZENG Lian-Shan, CHEN Nian-Ping, LIN Mu-Sheng, MO Ai, ZHOU Yu, HUANG Cun-Lin. Clinical evaluation of efficacy of ulinastatin in treatment of patients with acute pancreatitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 828-830.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[4]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[5]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[6]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[7]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[8]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[9]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[10]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[11]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[12]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[13]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[14]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[15]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.